<DOC>
	<DOCNO>NCT01334073</DOCNO>
	<brief_summary>The aim study determine MTD combination everolimus plus axitinib solid tumor , especially RCC .</brief_summary>
	<brief_title>Study Combination Axitinib Plus Everolimus Patients With Malignant Advanced Solid Tumors</brief_title>
	<detailed_description>Phase I study combination axitinib ( AX ) plus everolimus ( EV ) patient malignant advance solid tumor . - To determine recommend dose phase II study combination AX + EV - To determine safety profile predictive factor toxicity , pharmacokinetics ( PK ) , efficacy adult solid tumor . - To assess functional vascular imaging ( FVI ) surrogate marker activity , biomarkers predictive activity preliminary efficacy data metastatic RCC , untreated antiangiogenics . Phase I , multicentre , open-label , non-randomized , sequential algorithm base dose-finding ( 3+3 ) , clinical study successive cohort patient . Patients take drug orally , every day , without plan rest period ( AX bid EV day ) . By convention one cycle 28 day . At first cycle patient take one week AX single agent start EV . Patients treat increase dose level ( DLs ) successive cohort 3-6 patient accord number patient dose limit toxicity ( DLT ) maximum tolerate dose ( MTD ; i.e . DL &lt; = 1/6 patient experience DLT first cycle ) . All decision concern qualification DLT , dose escalation , study termination , inclusion additional patient , take Trial Monitoring Committee.. The MTD high recommend dose single agent . Six additional patient enter MTD confirm feasibility dose preliminarily assess efficacy combination patient RCC untreated antiangiogenics . Three level dose explore .</detailed_description>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<criteria>Inclusion criterion Histologically proven advance adult solid tumor , exception Hodgkin non Hodgkin lymphoma . Patients hepatocellular carcinoma ( HCC ) may enrol without histological documentation meet consensus noninvasive diagnostic criterion . Failure contraindication standard therapy , except patient advanced renal cell carcinoma , enrol recommend dose naïve previous line therapy metastatic . Age &gt; 18 year ECOG Performance status ( PS ) 01 Life expectancy &gt; 3 month Measurable/evaluable disease accord RECIST CRITERIA version 1.0 Acceptable biological value : Hemoglobin &gt; 10g /dL ; neutrophil &gt; 1.5 x 109/L ; platelet &gt; 100 x 109/L , AST ALT &lt; 2.5 x upper normal limit ( UNL ) , &lt; 5 x UNL case liver metastasis , GGT &lt; 3 x upper normal limit ( UNL ) , PAL &lt; 2.5 x upper normal limit ( UNL ) , &lt; 5 x UNL case liver metastasis , serum bilirubin &lt; 1.5 x ULN , creatinine clearance ( Cockroft &amp; Gault formula ) &gt; 60 mL/min . 24 hour proteinuria ≤ 1 g/24 h Albumin &gt; 30 g/l Amylase lipase ≤ 1.5 UNL Electrolytes ( calcium , sodium , potassium , chlore , magnesium , phosphate ) normal range . Supplementation could possible study entry . Total cholesterol ≤ 2.5 UNL Triglycerides ≤ 2.5 UNL BP &lt; 140/90 Washout period last anticancer therapy , include radiation surgery &gt; 3 week recovery toxicity NCICTC grade &lt; 1 . Written informed Consent . Use effective contraceptive method ( Intrauterine device , oral combine contraceptive ) woman childbearing age whose partner include trial . Patient french social security . Additional inclusion criterion association axitinib plus everolimus period No toxicity NCICTC grade &gt; 2 end axitinib alone period start axitinib everolimus ( cycle 1 ) BP &lt; 140/ 90 Exclusion criterion Brain metastasis Severe underlie cardiovascular disease , even medically control , angina pectoris , myocardial infarction , cardiac insufficiency , cardiac failure , cerebral stroke , low limb ischemic disease , thromboembolic disease , patient , , investigator 's opinion high risk arterial venous thromboembolism . Hepatitis B C carrier chronic state Uncontrolled hypertension , diabetes mellitus despite medical treatment . Inability swallow pill Unresolved pneumopathy , need antibiotherapy Any medical social condition , ; investigator 's opinion , would jeopardize patient 's safety , patient 's compliance protocol , interpretation study result . These condition include ( limited ) : severe infection , cardiac failure , chronic gastrointestinal disease compromise oral drug absorption , psychiatric illness , foreseeable poor treatment compliance oral medication , patient live far away investigational center , etc… Hypersensitivity Axitinib Everolimus Participation another clinical trial , use unapproved medication within 4 week prior study treatment initiation . Pregnant lactating woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Phase I</keyword>
	<keyword>Axitinib</keyword>
	<keyword>Everolimus</keyword>
	<keyword>Maximum tolerate dose ( MTD )</keyword>
	<keyword>solid tumor</keyword>
	<keyword>Renal cell cancer ( RCC )</keyword>
	<keyword>Pharmacokinetics ( PK/PD )</keyword>
</DOC>